Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Belzutifan Patent Expiration

Belzutifan is Used for treating advanced renal cell carcinoma after previous treatment with specific inhibitors. It was first introduced by Merck Sharp And Dohme Corp A Sub Of Merck And Co Inc in its drug Welireg on Aug 13, 2021.


Belzutifan Patents

Given below is the list of patents protecting Belzutifan, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Welireg US9908845 Aryl ethers and uses thereof Sep 05, 2034 Merck Sharp Dohme
Welireg US9969689 Aryl ethers and uses thereof Sep 05, 2034 Merck Sharp Dohme
Welireg USRE49948 Aryl ethers and uses thereof Sep 05, 2034 Merck Sharp Dohme


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Belzutifan's patents.

Given below is the list recent legal activities going on the following patents of Belzutifan.

Event Date Patent/Publication
Patent litigations
transaction for FDA Determination of Regulatory Review Period 30 Jan, 2024 US9969689
transaction for FDA Determination of Regulatory Review Period 30 Jan, 2024 US9908845
transaction for FDA Determination of Regulatory Review Period 11 Dec, 2023 US9969689
transaction for FDA Determination of Regulatory Review Period 11 Dec, 2023 US9908845
Second letter to regulating agency to determine regulatory review period 30 May, 2023 US9969689
Second letter to regulating agency to determine regulatory review period 30 May, 2023 US9908845
Letter from FDA or Dept of Agriculture re PTE application 13 Sep, 2022 US9969689
Letter from FDA or Dept of Agriculture re PTE application 13 Sep, 2022 US9908845
Patent Term Extension (156) Dismissed 12 Jan, 2022 US9969689
Patent Term Extension (156) Dismissed 12 Jan, 2022 US9908845



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳